Beone Medicines (ONC) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $47.2B
- As of Nov 17, 2026
- P/E
- 51.53x
- Trailing twelve months
- P/B
- 8.11x
- Latest reported equity
- P/S
- 7.14x
- Trailing twelve months
- ROE
- 15.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $47.2B
- As of Nov 17, 2026
- P/E
- 51.53x
- Trailing twelve months
- P/B
- 8.11x
- Latest reported equity
- P/S
- 7.14x
- Trailing twelve months
- ROE
- 15.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
51.53x
P/B
8.11x
P/S
7.14x
Earnings and dividend metrics▾
Earnings
EPS
$0.62
Earnings per share
BPS
$3.92
Book value per share
ROE
15.7%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $0.62 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.92 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 15.7%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 33.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.41B+33.9%
$1B
Jul–Sep '24
$1.41B
Jul–Sep '25
$1.89B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 5, 2026.
- Earnings per share increased 212.5% from the same quarter a year earlier.
- Revenue increased 33.9% from the same quarter a year earlier.
- Operating income increased 157.1% from the same quarter a year earlier.
- Net income increased 208.0% from the same quarter a year earlier.
Filed Nov 5, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Wang XiaodongDirector · Nov 9, 2026Gift1,183 shares · $0Avg. price $04,586,930 shares held after
- Ball Titus B.Principal Accounting Officer · Nov 6, 2026Open-market sale1,559 shares · $632KAvg. price $405.5659
Show 2 price lots
- 1,533 shares × $405.5528$622K
- 26 shares × $406.34$11K
- Ball Titus B.Principal Accounting Officer · Nov 6, 2026Option exercise1,559 shares · $291KAvg. price $186.4178
Show 2 price lots
- 880 shares × $207.55$183K
- 679 shares × $159.03$108K
- Lee Chan HenrySVP, General Counsel · Nov 5, 2026Open-market sale1,115 shares · $447KAvg. price $400.8161
Show 2 price lots
- 660 shares × $400$264K
- 455 shares × $402$183K
- Wang XiaodongDirector · Oct 27, 2026Open-market sale31,028 shares · $11.3MAvg. price $362.9667
Show 11 price lots
- 8,148 shares × $363.242$3.0M
- 6,903 shares × $366.2205$2.5M
- 3,965 shares × $365.4293$1.4M
- 2,841 shares × $363.9492$1.0M
- 2,331 shares × $362.3503$845K
- 1,681 shares × $358.7462$603K
- 1,440 shares × $355.616$512K
- 1,280 shares × $359.7219$460K
- 1,239 shares × $357.5386$443K
- 880 shares × $355.5595$313K
- 320 shares × $360.6363$115K
- Wang XiaodongDirector · Oct 27, 2026Option exercise31,028 shares · $1.1MAvg. price $36.931,028 shares held after
- Wang XiaodongDirector · Oct 13, 2026Open-market sale31,027 shares · $10.9MAvg. price $350.987
Show 5 price lots
- 10,361 shares × $350.4741$3.6M
- 7,167 shares × $349.5613$2.5M
- 6,558 shares × $352.5691$2.3M
- 5,681 shares × $351.3958$2.0M
- 1,260 shares × $353.2367$445K
- Wang XiaodongDirector · Oct 13, 2026Option exercise31,027 shares · $1.1MAvg. price $36.931,027 shares held after
- Lee Chan HenrySVP, General Counsel · Sep 30, 2026Open-market sale1,115 shares · $418KAvg. price $3750 shares held after
- Wang XiaodongDirector · Sep 28, 2026Open-market sale31,028 shares · $11.3MAvg. price $364.7853
Show 10 price lots
- 14,525 shares × $366.5783$5.3M
- 4,239 shares × $362.1675$1.5M
- 3,499 shares × $363.0995$1.3M
- 3,419 shares × $364.0675$1.2M
- 2,241 shares × $361.0529$809K
- 2,047 shares × $365.8479$749K
- 738 shares × $367.2252$271K
- 160 shares × $356.9662$57K
- 120 shares × $358.7067$43K
- 40 shares × $359.16$14K
- Wang XiaodongDirector · Sep 28, 2026Option exercise31,028 shares · $1.1MAvg. price $36.931,028 shares held after
- Wang XiaodongDirector · Sep 8, 2026Open-market sale24,749 shares · $8.6MAvg. price $349.2531
Show 3 price lots
- 10,688 shares × $349.2834$3.7M
- 7,492 shares × $348.3146$2.6M
- 6,569 shares × $350.2741$2.3M
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Beone Medicines (ONC) stock information
NASDAQ
Beone Medicines (ONC) is listed on NASDAQ. Its market capitalization is about $47.2B. On trailing-twelve-month earnings the P/E ratio is 51.53, and the P/B ratio is 8.11. Return on equity is 15.7%. These figures are computed in-house from official filings and are reference information only.
Beone Medicines — frequently asked questions
- What is the P/E ratio of Beone Medicines (ONC)?
- On a trailing-twelve-month basis, ONC trades at a P/E ratio of 51.53. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Beone Medicines?
- ONC has a market capitalization of about $47.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.